Autologous and personalised cell and gene therapies (CGTs) represent one of the most promising frontiers in modern medicine offering curative potential for conditions once deemed untreatable. However, realising their full potential at scale remains a complex challenge for life sciences manufacturers.
Unlike traditional pharmaceuticals, autologous CGTs require a scale-out approach managing multiple small, patient-specific batches rather than increasing the size of a single batch. This creates a range of unique challenges: high costs, time-sensitive production, strict regulatory scrutiny, and the need for precise data integrity and traceability.
To overcome these hurdles, forward-thinking organisations are embracing advanced digital strategies that enable:
- Intelligent automation and closed-loop process control
- Real-time monitoring and predictive analytics
- Digital batch records and guided workflows
- End-to-end traceability from vein-to-vein
- AI and digital twins for process optimisation and decision support
- Secure, open automation architectures that promote collaboration
At Emerson, we understand that digital transformation is not just a technological upgrade, it’s a strategic imperative. Our new white paper, “Digital Excellence for Advanced Therapies”, offers practical insights and proven approaches to help life sciences organisations build scalable, compliant, and future-ready CGT manufacturing environments.
Whether you’re looking to reduce batch variability, accelerate time-to-patient, or ensure regulatory compliance across your value chain, this resource is an essential guide for digital leaders in life sciences. Download the Digital Excellence for Advanced Therapies white paper to find out more.
